The objective was to provide a comprehensive summary of existing evidence on the efficacy
and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) for the …

Anemia is one of the most common chronic kidney disease (CKD) complications. It
negatively affects patients' quality of life and clinical outcomes. The pathophysiology of …

Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are oral
alternatives to current standard-of-care treatments for anaemia in chronic kidney disease …

Abstract Von Hippel–Lindau protein (VHL) is essential to hypoxic regulation of cellular
processes. VHL promotes proteolytic clearance of hypoxia‐inducible transcription factors …

Introduction Thromboembolic events have occurred in clinical trials of roxadustat. This post
hoc analysis explored potential factors related to thromboembolic events in dialysis …

Introduction Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH)
inhibitor, can stimulate erythropoiesis. Our objective was to evaluate the efficacy and safety …

Introduction The breakthrough in erythropoietin-stimulating agents in the 1990s improved
the prognosis and treatment of complications in chronic kidney disease patients and renal …

Purpose To review current evidence on the efficacy and safety outcomes of HIF-PHIs in
chronic kidney disease (CKD) populations with an emphasize on the safety profile. Methods …

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) have emerged as a novel
therapeutic class for treating anemia in patients with chronic kidney disease. Small molecule …

Objective: The objective was to review the safety and efficacy of daprodustat, a hypoxia-
inducible factor–prolyl hydroxylase inhibitor (HIF-PHI) in the treatment of anemia of chronic …